XURIDEN
Peakuridine triacetate
NDAORALGRANULEPriority Review
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XURIDEN (uridine triacetate) is an oral granule formulation of a pyrimidine analog approved in 2015. It is indicated for emergency treatment of acute fluorouracil (5-FU) overdose and other severe adverse reactions caused by 5-FU or capecitabine chemotherapy. The drug works by providing exogenous uridine to bypass the blocked de novo pyrimidine synthesis pathway and reduce toxic metabolite accumulation.
Peak
Product is in peak commercial phase with moderate competitive pressure (30% intensity), suggesting stable mid-sized commercial operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
XURIDEN roles focus on niche oncology commercialization and medical education in emergency chemotherapy settings. Career opportunities emphasize specialized customer engagement and clinical support rather than large-scale commercial scale-up.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.